Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology. Radius' lead product, TYMLOSÂŽ (abaloparatide) injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in osteoporosis; the investigational drug elacestrant (RAD1901) for potential use in hormone-receptor positive breast cancer; and the investigational drug RAD140 under investigation for potential use in hormone-receptor positive breast cancer. Source
No articles found.
Neurohacker Collective was founded in 2015 with the mission of creating best in cl...
Neurohacker Collective was founded in 2015 with...
Trovagene is a clinical-stage, oncology therapeutics company, taking a precision m...
Trovagene is a clinical-stage, oncology therape...
Lianluo Smart Limited is a professional smart service products provider, which dev...
Lianluo Smart Limited is a professional smart s...
Innovate is a publicly traded (Nasdaq: INNT) clinical stage biotechnology company ...
Innovate is a publicly traded (Nasdaq: INNT) cl...
Calithera is a clinical-stage biopharmaceutical company pioneering the discovery a...
Calithera is a clinical-stage biopharmaceutical...
Fortress Biotech ("Fortress" or "the Company") is an innovative biopharmaceutical ...
Fortress Biotech ("Fortress" or "the Company") ...
At GlycoMimetics, we are committed to helping to make a difference in the lives of...
At GlycoMimetics, we are committed to helping t...
Join the National Investor Network and get the latest information with your interests in mind.